Cocrystal Pharma, Inc. to Post Q3 2024 Earnings of ($0.59) Per Share, Zacks Small Cap Forecasts (NASDAQ:COCP)

Cocrystal Pharma, Inc. (NASDAQ:COCP) – Research analysts at Zacks Small Cap issued their Q3 2024 EPS estimates for Cocrystal Pharma in a report released on Tuesday, April 23rd. Zacks Small Cap analyst D. Bautz expects that the company will post earnings of ($0.59) per share for the quarter. The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($2.18) per share. Zacks Small Cap also issued estimates for Cocrystal Pharma’s FY2026 earnings at ($2.58) EPS.

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Cocrystal Pharma in a research note on Thursday, April 4th.

Cocrystal Pharma Trading Down 4.0 %

COCP opened at $1.50 on Thursday. The firm has a 50-day moving average price of $1.49 and a 200-day moving average price of $1.63. Cocrystal Pharma has a twelve month low of $1.33 and a twelve month high of $3.29.

Cocrystal Pharma (NASDAQ:COCP) last posted its earnings results on Thursday, March 28th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.13.

About Cocrystal Pharma

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections.